Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Bohlen

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Cancer Metastasis Reviews|June 16, 2000
Engineering antibodies for the clinicP Holliger, H Bohlen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Report on the workshop biology of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995J Wolf, H Bohlen, V Diehl
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
CD30: cytokine-receptor, differentiation marker or a target molecule for specific immune response?V Diehl, H Bohlen, J Wolf
Journal of the American Academy of Dermatology|March 1, 1993
Efficacy of cyclophosphamide in toxic epidermal necrolysisM Hertl, H Bohlen, H F Merk
Medizinische Klinik (Munich, Germany : 1983)|January 5, 2002
[Artificial sweeteners--are they potentially carcinogenic?]M R Weihrauch, V Diehl, H Bohlen
Archives of Dermatology|February 1, 1992
T-cell subsets in drug-induced toxic epidermal necrolysisM Hertl, H F Merk, H Bohlen
Journal of Immunological Methods|January 20, 1998
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatographyO Manzke, H Tesch, V Diehl, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 18, 1998
[Pathogenesis and therapy of Hodgkin lymphoma]H Tesch, H Bohlen, J Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1995
Serum cytokine levels correlate with clinical parameters in Hodgkin's diseaseM Gorschlüter, H Bohlen, D Hasenclever, et al.
International Journal of Cancer|March 17, 2001
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responsesO Manzke, H Tesch, J Lorenzen, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Cancer Metastasis Reviews|June 16, 2000
Engineering antibodies for the clinicP Holliger, H Bohlen
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1996
Report on the workshop biology of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995J Wolf, H Bohlen, V Diehl
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1994
CD30: cytokine-receptor, differentiation marker or a target molecule for specific immune response?V Diehl, H Bohlen, J Wolf
Journal of the American Academy of Dermatology|March 1, 1993
Efficacy of cyclophosphamide in toxic epidermal necrolysisM Hertl, H Bohlen, H F Merk
Medizinische Klinik (Munich, Germany : 1983)|January 5, 2002
[Artificial sweeteners--are they potentially carcinogenic?]M R Weihrauch, V Diehl, H Bohlen
Archives of Dermatology|February 1, 1992
T-cell subsets in drug-induced toxic epidermal necrolysisM Hertl, H F Merk, H Bohlen
Journal of Immunological Methods|January 20, 1998
Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatographyO Manzke, H Tesch, V Diehl, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 18, 1998
[Pathogenesis and therapy of Hodgkin lymphoma]H Tesch, H Bohlen, J Wolf, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1995
Serum cytokine levels correlate with clinical parameters in Hodgkin's diseaseM Gorschlüter, H Bohlen, D Hasenclever, et al.
International Journal of Cancer|March 17, 2001
Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responsesO Manzke, H Tesch, J Lorenzen, et al.
Pageof 7